CEO Amir Reichman will discuss recent business updates including:
The nanosized antibody (NanoAb) pipeline development collaboration with the Max Planck Institute for Multidisciplinary Sciences (MPG) and University Medical Center Göttingen (UMG), Germany
In-house preparations for the manufacturing of NanoAbs at the Company's GMP biologics manufacturing facility in Jerusalem
Negotiations regarding restructuring of the European Investment Bank's loan providing continued long-term support for BiondVax.
FY'21 financial results
The webinar will also feature Professor Dr. Matthias Dobbelstein, a Fellow at MPG and Professor at UMG, who will briefly discuss the recent NanoAb research results. Time permitting, the webinar will be opened to questions and answers.